Introduction
In large parts of the world vaccination has successfully eliminated measles as a significant causes of morbidity and mortality. 1 However, it is one of the leading causes of child mortality and in 2011, contributed 158000 deaths globally. 2 Measles virus is highly infections and is transmitted by aerosols generated during coughing or by direct contact with contaminated respiratory secretion. After an incubation time of almost two weeks, disease starts with a prodromal phase of fever cough and coryza. A few days later a generalized maculopapular skin rash appears, often in combination with conjuctivities. 3 Measles is associated with a transient but profound immunosuppression, resulting in an increased susceptibility to opportunistic infections. This often leads to complications like pneumonia, diarrhoea and otitis media which are the most important determinants of measles morbidity and mortality. 3, 4 Paradoxically, the disease is also associated with the induction of strong measles virus specific humoral and cellular immune response, resulting in life-long immunity. 5 Before the introduction of the measles vaccine, the measles virus caused millions of deaths worldwide. 6 Measles vaccination is the only hope to reduce incidence and mortality of this disease. WHO recommends two doses of vaccination with flexibility of schedule as 15% of vaccinated children fail to develop immunity from first vaccination dose. However, routine vaccination in many countries have caused measles to become relatively uncommon. In Bangladesh, with the successful implementation of the Expanded Programme on Immunization, measles incidence declined. During 2000-2016, incidence of measles cases decreased 84%, from 40.0 to 6.0 per million. 7 Measles is relatively uncommon among infants of developed countries due to the protection offered by maternal antibodies. In developing countries, where there is a high degree of wild-type measles transmission, infants and children are at greater risk of being exposed shortly after maternal antibodies have waned. This often occurs as early as at 5-6 months of age. 8 Measles at an early age is associated with serious complications and an increased risk of mortality, necessitating vaccinations as early as possible. In developed countries live attenuated vaccines are safe, immunogenic and effective. However, due to the early loss of maternal antibodies in infants in developing countries, it has been recommended that measles vaccine should be administered from 9 months of age. 9 This strategy, however, leaves a window of high risk between 4 and 9 months of age.
In this report, we presented demographic characteristics of patients who had the diagnosis of measles at Dhaka Shishu (Children) Hospital and occurrence of measles from the time of vaccination.
Materials and Methods
This retrospective study was conducted on patient who was diagnosed as measles at Dhaka Shishu (Children) Hospital, the largest tertiary care pediatric hospital in Bangladesh, between 1 st January 2017 to 30 th April 2017. The study was approved by Ethical Committee of Dhaka Shishu (Children) Hospital. The disease was diagnosed with clinical suspicion and laboratory confirmation, standard isolation airborne precautions were applied for every patient who was suspected measles until the result of ELISA. The diagnosis of measles was confirmed by measles specific immunoglobulin M (IgM) antibody positivity in serum sample and was included in the study. After selected the cases reporting done sample has collected and sent to the NPB and report has collected after seven days. This study confirmed measles serologically, thus avoiding the potential bias in vaccine effectiveness from non-specific diagnosis. Age, gender, vaccination status, clinical and laboratory findings were recorded. All relevant data was extracted from chart and electronic records from the hospital. Data were analyzed by using SPSS version 21.
Results
Total 13864 patients were admitted during the study period and among them 23 were confirmed as measles. Rate of measles was found as 0.16% among hospitalized children. There were 17 (73.90%) male patients and 6 (26.10%) female patients with a male female ratio of 2.8:1 (Fig.-1) . Among 23 measles patients vaccine was not given in 2(8.7%) patients, one dose of vaccine was given in 19(82.60%) patients and two doses of vaccine were given in 2(8.7%) patients. Most of the measles patients came after one vaccination which means after first dose (Fig.-2) .
Among the measles patients age of onset was <9 months in 2(8.7%), 9-12 months in 8(34.8%), 13-14 months in 11(47.8%) and 15 months and above in 2(8.6%) cases (Fig.-3) .
the maximum number of infants. Among 23 measles patients vaccine was not given in 2(8.7%) patients, one dose of vaccine was given in 19(82.60%) patients and two doses of vaccine were given in 2(8.7%) patients. Most of the measles patients came after one vaccination which means after first dose. WHO recommends delayed measles vaccination until maternal antibody has waned. Research in the USA has shown that cell mediated responses to measles vaccine given to children at 6 months of age were similar to those in children vaccinated at 9 or 12 months of age but antibody responses were diminished by maternal antibody. However 6 months after a boost at 12 months of age protective levels of antibody were achieved in 86% of the youngest children while T-cell proliferative responses changed little in any of the age groups. 13 Vaccine effectiveness of an early two dose schedule during a large measles epidemic in Florida was 99%. 14 An additional early measles vaccine given to children at 4 months of age induced a predominant CD4 T-cell response at 9 months and rapid development of high antibody concentrations after booster doses. 15 In low income countries, maternal antibody levels against measles may be low and severe outbreaks of measles can occur in infants before the recommended age of vaccination at 9 months. 16 However, early measles vaccine may improve child survival by reducing mortality. 17 Early two dose schedules of measles vaccine given at 6 and 9 months of age were recommended by WHO to control outbreaks and for use in countries with high attack rates of measles in infancy. Now WHO recommends such schedules in areas with a high incidence of HIV and measles. 18 An early two dose schedule would fit well and protects the very young and enhances child survival. 16, 17 The current measles vaccination policy was based on children born to naturally infected mothers. Such children may not lose protection from maternal antibodies until around 7 to 9 months of age. 19 The situation has changed since the 1980s. Most low income countries have had measles vaccination programmes for the past 30-35 years. As a consequence many mothers have been immunized and have not had natural measles infection. A new group of children born to immunized mothers therefore exists who may lose protection early. 16 This situation should lead to reconsideration of the policy for measles vaccination. An early two dose measles vaccination strategy could strengthen the current efforts to control measles and reduce measles mortality. Among the measles patients age of onset was <9 months in 2(8.7%), 9-12 months in 8(34.8%), 13-14 months in 11(47.8%) and 15 months and above in 2(8.6%) cases. Akramuzzaman et al in Bangladesh found 23% of measles cases before 9 months of age and 19% between 9-11 months of hospitalized children admitted with measles. 12 In Bangladesh the timing of the first dose of measles vaccine at 9 months of age to minimize interference from maternal antibody and to provide protection for
